[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100409197":3},{"organization":4,"armGroups":7,"interventions":8,"overallOfficials":13,"centralContacts":17,"locations":27,"responsibleParty":43,"collaborators":46,"id":49,"slug":7,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":7,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":7,"enrollmentInfo":57,"targetDuration":60,"studyType":61,"phases":7,"briefSummary":62,"conditions":63,"keywords":68,"overallStatus":29,"whyStopped":7,"lastUpdateSubmitDate":75,"lastUpdatePostDateStruct":76,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},{"fullName":5,"class":6},"Sunnybrook Health Sciences Centre","OTHER",null,[9],{"type":10,"name":11,"description":12,"armGroupLabels":7,"otherNames":7},"DIAGNOSTIC_TEST","Needle Core Biopsies","Not an interventional study",[14],{"name":15,"affiliation":5,"role":16},"Katarzyna J Jerzak, MD MSc FRCPC","PRINCIPAL_INVESTIGATOR",[18,23],{"name":15,"role":19,"phone":20,"phoneExt":21,"email":22},"CONTACT","416-480-6100","5248","katarzyna.jerzak@sunnybrook.ca",{"name":24,"role":19,"phone":20,"phoneExt":25,"email":26},"Hon S Leong","5748","hon.leong@sri.utoronto.ca",[28],{"facility":5,"status":29,"city":30,"state":31,"zip":32,"country":33,"cosmosGeoPoint":34,"geoPoint":39,"contacts":40},"RECRUITING","Toronto","Ontario","M4N 3M5","Canada",{"type":35,"coordinates":36},"Point",[37,38],-79.39864,43.70643,{"lat":38,"lon":37},[41,42],{"name":15,"role":19,"phone":20,"phoneExt":21,"email":22},{"name":24,"role":19,"phone":20,"phoneExt":25,"email":26},{"type":16,"investigatorFullName":44,"investigatorTitle":45,"investigatorAffiliation":5,"oldNameTitle":7,"oldOrganization":7},"Dr. Katarzyna Jerzak","Medical Oncologist & Associate Scientist",[47],{"name":48,"class":6},"AFP Innovation Fund","100409197",false,"NCT04608357","Integrated Patient Avatars for Guiding Systemic Therapy Treatments in Metastatic Breast Cancer Patients","Integrated Patient Avatars for Guiding Systemic Therapy Treatments: \"Intuition-Free\" Decisions in Metastatic Breast Cancer Patients","Inclusion Criteria:\n\n1. Age 18+.\n2. Metastatic breast cancer irrespective of subtype.\n3. Measurable disease as per RECIST 1.1 criteria.\n4. Metastatic disease involving the lymph nodes and\u002For visceral organs is required.\n5. Willingness to undergo a biopsy prior to the start of planned systemic therapy.\n\nExclusion Criteria:\n\n1. Lack of feasibility to obtain a core biopsy of a metastatic site other than the bone (e.g. a metastatic lesion cannot be safely sampled due to proximity to vasculature).\n2. Inability to provide informed consent.","ALL","18 Years",{"count":58,"type":59},25,"ESTIMATED","3 Years","OBSERVATIONAL","The investigators propose to use clinically validated patient avatar technology (\"PDXovo\") that can test multiple drugs against patients' cancers to identify the most promising systemic therapy for each individual.",[64,65,66,67],"Breast Cancer","Breast Neoplasms","Metastatic Breast Cancer","Cancer, Breast",[69,70,71,72,73,74],"metastatic breast cancer","systemic therapy","needle core biopsy","PDXovo","feasibility study","tumor take rate","2025-01-17",{"date":77,"type":78},"2025-01-20","ACTUAL",{"date":80,"type":78},"2021-07-21",{"date":82,"type":59},"2027-12",{"name":5,"class":6},1]